Back to Journals » Substance Abuse and Rehabilitation » Volume 7

Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review

Authors Copeland J, Pokorski I

Received 7 December 2015

Accepted for publication 10 February 2016

Published 3 May 2016 Volume 2016:7 Pages 41—53

DOI https://doi.org/10.2147/SAR.S89857

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Professor Li-Tzy Wu

Video abstract presented by Izabella Pokorski.

Views: 221

Jan Copeland, Izabella Pokorski

UNSW Medicine, University of New South Wales, Sydney, NSW, Australia

Abstract: Cannabis is the most widely used and variably regulated drug in the world, with increasing trends of use being reported in the US, Australia, Asia, and Africa. Evidence has shown a decrease in the age of commencement of cannabis use in some developed countries and a prolongation of risk of initiation to cannabis use beyond adolescence among more recent users. Cannabis use is associated with numerous health risks and long-term morbidity, as well as risk of developing cannabis-use disorders. Cannabis users infrequently seek professional treatment, and normally do so after a decade of use. Cannabis-use disorders are currently treated using a selection of psychosocial interventions. Severity of withdrawal is a factor that increases the risk of relapse, and is the target of pharmacotherapy studies. Currently, there is no approved pharmacotherapy for cannabis-use disorders. A number of approaches have been examined, and trials are continuing to find a safe and effective medication with little abuse liability.

Keywords: marijuana, treatment, intervention, withdrawal, cannabinoid

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Factors affecting treatment adherence to atomoxetine in ADHD: a systematic review

Treuer T, Méndez L, Montgomery W, Wu S

Neuropsychiatric Disease and Treatment 2016, 12:1061-1083

Published Date: 3 May 2016

Modern management of malignant pleural mesothelioma

Patel SC, Dowell JE

Lung Cancer: Targets and Therapy 2016, 7:63-72

Published Date: 3 May 2016

Mitral regurgitation: challenges and solutions

Ejiofor JI, Cohn L, Kaneko T

Research Reports in Clinical Cardiology 2016, 7:61-67

Published Date: 3 May 2016

Design, synthesis, and biological evaluation of 3-vinyl-quinoxalin-2(1H)-one derivatives as novel antitumor inhibitors of FGFR1

Liu Z, Yu S, Chen D, Shen G, Wang Y, Hou L, Lin D, Zhang JS, Ye F

Drug Design, Development and Therapy 2016, 10:1489-1500

Published Date: 3 May 2016

Diagnostic pitfalls in a young Romanian ranger with an acute psychotic episode

Nagy EE, Rácz A, Urbán E, Terhes G, Berki T, Horváth E, Georgescu AM, Zaharia-Kézdi IE

Neuropsychiatric Disease and Treatment 2016, 12:961-967

Published Date: 3 May 2016

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

A new recombinant factor VIII: from genetics to clinical use

Kannicht C, Kohla G, Tiemeyer M, Walter O, Sandberg H

Drug Design, Development and Therapy 2015, 9:3817-3819

Published Date: 23 July 2015